Open AccessEfficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques
Author(s) -
Hannah A. D. King,
Michael Joyce,
Inès Lakhal-Naouar,
Aslaa Ahmed,
Camila Macedo Cincotta,
Caroline Subra,
Kristina K. Peachman,
Holly R. Hack,
Rita E. Chen,
Paul Thomas,
WeiHung Chen,
Rajeshwer S. Sankhala,
Agnes Hajduczki,
Elizabeth Martinez,
Caroline E. Peterson,
William C. Chang,
Misook Choe,
Catherine Arnott Smith,
Jarrett A. Headley,
Hanne Andersen Elyard,
Anthony Cook,
Alexander R.A. Anderson,
Kathryn McGuckin Wuertz,
Dong Ming,
Isabella Swafford,
James Brett Case,
Jeffrey R. Currier,
Kerri G. Lal,
Mihret F. Amare,
Vincent Dussupt,
Sebastian Molnar,
Sharon Daye,
Xiankun Zeng,
Erica K. Barkei,
Kendra J. Alfson,
Hilary Staples,
Ricardo Carrión,
Shelly J. Krebs,
Dominic PaquinProulx,
Nicos Karasavvas,
Victoria R. Polonis,
Linda L. Jagodzinski,
Sandhya Vasan,
Paul T. Scott,
Yaoxing Huang,
Manoj S. Nair,
David D. Ho,
Natalia de Val,
Michael S. Diamond,
Mark G. Lewis,
Mangala Rao,
Gary R. Matyas,
Gregory D. Gromowski,
Sheila A. Peel,
Nelson L. Michael,
Kayvon Modjarrad,
Diane L. Bolton
Publication year - 2021
Publication title -
proceedings of the national academy of sciences of the united states of america
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.2106433118
Subject(s) - immunogenicity , virology , antibody , neutralizing antibody , vaccination , coronavirus , biology , immunology , respiratory system , titer , viral replication , medicine , virus , covid-19 , infectious disease (medical specialty) , disease , pathology , anatomy
Emergence of novel variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) underscores the need for next-generation vaccines able to elicit broad and durable immunity. Here we report the evaluation of a ferritin nanoparticle vaccine displaying the receptor-binding domain of the SARS-CoV-2 spike protein (RFN) adjuvanted with Army Liposomal Formulation QS-21 (ALFQ). RFN vaccination of macaques using a two-dose regimen resulted in robust, predominantly Th1 CD4+ T cell responses and reciprocal peak mean serum neutralizing antibody titers of 14,000 to 21,000. Rapid control of viral replication was achieved in the upper and lower airways of animals after high-dose SARS-CoV-2 respiratory challenge, with undetectable replication within 4 d in seven of eight animals receiving 50 µg of RFN. Cross-neutralization activity against SARS-CoV-2 variant B.1.351 decreased only approximately twofold relative to WA1/2020. In addition, neutralizing, effector antibody and cellular responses targeted the heterotypic SARS-CoV-1, highlighting the broad immunogenicity of RFN-ALFQ for SARS-CoV-like Sarbecovirus vaccine development.